{"disease":{"id":"extended-adjuvant-treatment-of-early-breast-cancer","name":"extended adjuvant treatment of early breast cancer"},"drugs":{"marketed":[{"drug_id":"chembl-chembl1444","indication_name":"Extended adjuvant treatment of early breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LETROZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"letrozole-tablets","indication_name":"Extended Adjuvant Treatment of Early Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Letrozole tablets","company_name":"Al-Azhar University","drug_phase":"marketed","molecular_target":"","drug_class":"Aromatase Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"letrozole","guideline_body":"FDA label","recommendation":"Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy.","line_of_therapy":"extended adjuvant","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}